{"id":"W2924781650","doi":"10.1111/bjd.17919","title":"Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Memorial University of Newfoundland","funders":"LEO Pharma; Eli Lilly and Company; AstraZeneca; Galderma; Medac; AbbVie; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Celgene; Biogen; Gilead Sciences; Amgen; Pfizer","keywords":"Adalimumab; Medicine; Placebo; Dosing; Adverse effect; Hidradenitis suppurativa; Randomized controlled trial; Post-hoc analysis; Internal medicine; Clinical trial; Post hoc; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02073579,0.001068419,0.003369442,0.0005634167,0.0003483364,0.001678497,0.0009867662,0.001353581,0.00197332],"category_scores_gemma":[0.008201987,0.0004825951,0.003557178,0.0005937908,0.0008789812,0.001052913,0.0007182361,0.001983801,0.0002841821],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006967653,"about_ca_system_score_gemma":0.002068555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005552796,"about_ca_topic_score_gemma":0.001512847,"domain_scores_codex":[0.9926358,0.005367693,0.000554464,0.0004392748,0.000699953,0.0003028362],"domain_scores_gemma":[0.9938632,0.002545055,0.001591013,0.0006995364,0.0006301715,0.0006710166],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8876585,0.007360957,0.002727599,0.002985683,0.008832668,0.00004056263,0.0001611012,0.0008423338,0.007954028,0.0003779366,0.001335695,0.07972286],"study_design_scores_gemma":[0.8343623,0.1457115,0.008706396,0.0004460094,0.005976641,0.00007220278,0.00003671279,0.0004231488,0.001255461,0.0003575328,0.002605285,0.00004680178],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8893764,0.08499236,0.00549406,0.00143328,0.0007004892,0.01095508,0.002126834,0.0002087016,0.004712775],"genre_scores_gemma":[0.9470088,0.02147277,0.01390196,0.001627658,0.001491128,0.009866542,0.002547335,0.00007462256,0.002009114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02073579,"threshold_uncertainty_score":0.1096627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02522170362663017,"score_gpt":0.3089418987806154,"score_spread":0.2837201951539852,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}